References
- Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, et al. Longterm therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Neurosurg Focus 2014; 37: E4. doi: 10.3171/2014.9.FOCUS14502
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96. doi: 10.1056/NEJMoa043330
- Altieri R, Melcarne A, Soffietti R, Rudá R, Franchino F, Pellerino A, et al. Supratotal resection of glioblastoma: is less more? Surg Technol Int 2019; 35: 432-440. PMID: 31373379
- Certo F, Stummer W, Farah JO, Freyschlag C, Visocchi M, Morrone A, et al. Supramarginal resection of glioblastoma: 5-ALA fluorescence, combined intraoperative strategies and correlation with survival. J Neurosurg Sci 2019; 63: 625-32. doi: 10.23736/S0390-5616.19.04787-8
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system, Revise 4th edition. Lyon: IARC Press, 2016.
- Altieri R, Hirono S, Duffau H, Ducati A, Fontanella M, LA Rocca G, et al. Natural history of de novo high grade glioma: first description of growth parabola. J Neurosurg Sci 2020; 64: 399-403. doi: 10.23736/S0390-5616.17.04067-X
- Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353: 811-22. doi: 10.1056/NEJMra043666
- Gozé C, Blonski M, Le Maistre G, Bauchet L, Dezamis E, Page P, et al. Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas. Neuro Oncol 2014; 16: 1100-9. doi: 10.1007/s11060-008-9680-8
- Stensjøen AL, Solheim O, Kvistad KA, Håberg AK, Salvesen Ø, Berntsen EM. Growth dynamics of untreated glioblastomas in vivo. Neuro Oncol 2015; 17: 1402-11. doi: 10.1093/neuonc/nov029
- Hormuth DA, Weis JA, Barnes SL, Miga MI, Rericha EC, Quaranta V, et al. A mechanically coupled reaction–diffusion model that incorporates intra-tumoural heterogeneity to predict in vivo glioma growth. J Royal Soc Interface 2017; 14: 20161010. doi: 10.1098/rsif.2016.1010
- Raman F, Scribner E, Saut O, Wenger C, Colin T, Fathallah-Shaykh HM. Computational trials: unraveling motility phenotypes, progression patterns, and treatment options for glioblastoma multiforme. PLoS One 2016; 11: e0146617. doi: 10.1371/journal.pone.0146617
- Batchala PP, Muttikkal TJE, Donahue JH, Patrie JT, Schiff D, Fadul CE, et al. Neuroimaging-based classification algorithm for predicting 1p/19q-codeletion status in IDH -mutant lower grade gliomas. AJNR Am J Neuroradiol 2019; 40: 426-32. doi: 10.3174/ajnr.A5957
- Altieri R, Zenga F, Ducati A, Melcarne A, Cofano F, Mammi M, et al. Tumor location and patient age predict biological signatures of high-grade gliomas. Neurosurg Rev 2018; 41: 599-604. doi: 10.1007/s10143-017-0899-8
- Compes P, Tabouret E, Etcheverry A, Colin C, Appay R, Cordier N, et al. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016. J Neurooncol 2019; 142: 511-20. doi: 10.1007/s11060-019-03122-1
- Mikkelsen VE, Stensjøen AL, Granli US, Berntsen EM, Salvesen Ø, Solheim O, et al. Angiogenesis and radiological tumor growth in patients with glioblastoma. BMC Cancer 2018; 18: 862. doi: 10.1186/s12885-018-4768-9
- Pallud J, Taillandier L, Capelle L, Fontaine D, Peyre M, Ducray F, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012; 71: 729-39. doi: 10.1227/NEU.0b013e31826213de
- Pallud J, Mandonnet E, Duffau H, Kujas M, Guillevin R, Galanaud D, et al. Prognostic value of initial magnetic resonance imaging growth rates for world health organization grade II gliomas. Ann Neurol 2006; 60: 380-3. doi: 10.1002/ana.20946
- Mandonnet E, Delattre J, Tanguy M-L, Swanson KR, Carpentier AF, Duffau H, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 2003; 53: 524-8. doi: 10.1002/ana.10528
- Mandonnet E, Pallud J, Clatz O, Taillandier L, Konukoglu E, Duffau H, et al. Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm. Neurosurg Rev 2008; 31: 263-9. doi: 10.1007/s10143-008-0128-6
- Pallud J, Blonski M, Mandonnet E, Audureau E, Fontaine D, Sanai N, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol 2013; 15: 595-606. doi: 10.1093/neuonc/nos331
- Mandonnet E, Wait S, Choi L, Teo C. The importance of measuring the velocity of diameter expansion on MRI in upfront management of suspected WHO grade II glioma - case report. Neurochirurgie 2013; 59: 89-92. doi: 10.1016/j.neuchi.2013.02.005
- Zeppa P, Neitzert L, Mammi M, Monticelli M, Altieri R, Castaldo M, et al. How reliable are volumetric techniques for high-grade gliomas? A comparison study of different available tools. Neurosurgery 2020; nyaa282. [Ahead of print]. doi: 10.1093/neuros/nyaa282
- Jbabdi S, Mandonnet E, Duffau H, Capelle L, Swanson KR, Pélégrini-Issac M, et al. Simulation of anisotropic growth of low-grade gliomas using diffusion tensor imaging. Magn Reson Med 2005; 54: 616-24. doi: 10.1002/mrm.20625
- Gui C, Kosteniuk SE, Lau JC, Megyesi JF. Tumor growth dynamics in serially-imaged low-grade glioma patients. J Neurooncol 2018; 139: 167-75. doi: 10.1007/s11060-018-2857-x
- Yamashita T, Kuwabara T. Estimation of rate of growth of malignant brain tumors by computed tomography scanning. Surg Neurol 1983; 20: 464-70. doi: 10.1016/0090-3019(83)90029-0
- Schwartz M. A biomathematical approach to clinical tumor growth. Cancer 1961; 14: 1272-94. doi: 10.1002/1097-0142(196111/12)14:6<;1272::aid-cncr2820140618>3.0.co;2-h
- Harpold HLP, Alvord EC, Swanson KR. The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol 2007; 66: 1-9. doi: 10.1097/nen.0b013e31802d9000
- Laird AK. Dynamics of tumor growth. Br J Cancer 1964; 13: 490-502. doi: 10.1038/bjc.1964.55
- Chignola R, Foroni RI. Estimating the growth kinetics of experimental tumors from as few as two determinations of tumor size: implications for clinical oncology. IEEE Transactions on Biomed Eng 2005; 52: 808-15. doi: 10.1109/TBME.2005.845219
- Cochereau J, Herbet G, Rigau V, Duffau H. Acute progression of untreated incidental WHO Grade II glioma to glioblastoma in an asymptomatic patient. J Neurosurg 2016; 124: 141-5. doi: 10.3171/2014.12.JNS141851
- Shah AH, Madhavan K, Heros D, Raper DMS, Iorgulescu JB, Lally BE, et al. The management of incidental low-grade gliomas using magnetic resonance imaging: systematic review and optimal treatment paradigm. Neurosurg Focus 2011; 31: E12. doi: 10.3171/2011.9.FOCUS11219